Conference Proceedings

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Ben Tran, Lisa Horvath, Tanya B Dorff, Richard Greil, Jean-Pascal H Machiels, Felicia Roncolato, Karen A Autio, Matthew Rettig, Karim Fizazi, Martijn P Lolkema, Anthony C Fermin, Mark Salvati, Hosein Kouros-Mehr

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2020


Funding Acknowledgements

Amgen Inc.